Suppliers and packagers for generic pharmaceutical drug: bazedoxifene acetate; estrogens, conjugated

bazedoxifene acetate; estrogens, conjugated

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Wyeth Pharms	DUAVEE	bazedoxifene acetate; estrogens, conjugated	TABLET;ORAL	022247	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-1123-12	1 POUCH in 1 CARTON (0008-1123-12) / 2 BLISTER PACK in 1 POUCH / 15 TABLET, FILM COATED in 1 BLISTER PACK	2013-10-03
Wyeth Pharms	DUAVEE	bazedoxifene acetate; estrogens, conjugated	TABLET;ORAL	022247	NDA	U.S. Pharmaceuticals	63539-122-07	1 BLISTER PACK in 1 CARTON (63539-122-07) / 7 TABLET, FILM COATED in 1 BLISTER PACK	2013-11-15

Bazodexifene Acetate and Conjugated Estrogens: Key Supplier Landscape

Last updated: February 19, 2026

This report details the primary suppliers for bazedoxifene acetate and conjugated estrogens, critical active pharmaceutical ingredients (APIs) used in hormone replacement therapy and osteoporosis treatment. Understanding this supply chain is vital for pharmaceutical manufacturers and investors navigating market dynamics, regulatory compliance, and potential supply disruptions.

Who are the primary API manufacturers for bazedoxifene acetate?

Bazedoxifene acetate, a selective estrogen receptor modulator (SERM), is primarily manufactured by specialized API producers. The concentration of manufacturers for this complex molecule is a key factor in supply chain resilience.

• Key Manufacturers Identified:

  • Pfizer Inc.: While Pfizer markets the final drug product (Duavee®), it also has internal API manufacturing capabilities. The specific facilities and capacity for bazedoxifene acetate are proprietary, but its role as the originator and primary marketer suggests significant internal control over API supply.
  • Contract Development and Manufacturing Organizations (CDMOs): Several CDMOs globally are capable of producing bazedoxifene acetate, often under contract for generic drug manufacturers or smaller pharmaceutical companies. These include entities in India and China, which are significant hubs for API production. Specific company names are often subject to confidentiality agreements with their clients. However, companies with strong expertise in complex organic synthesis and cGMP (current Good Manufacturing Practices) compliance are prime candidates. These often include:
    • Divi's Laboratories Limited: A prominent Indian API manufacturer with a broad portfolio and strong regulatory track record. While not specifically advertising bazedoxifene acetate, its capabilities align with producing such molecules.
    • Lupin Limited: Another major Indian pharmaceutical company with significant API manufacturing capacity.
    • Chinese API Manufacturers: Numerous Chinese companies possess the chemical synthesis capabilities. Identifying specific suppliers without direct engagement is challenging due to market opacity and contractual exclusivity. However, those with FDA and EMA inspected facilities are the most relevant.

• Supply Chain Considerations:

  • The production of bazedoxifene acetate requires multi-step organic synthesis, demanding specialized expertise and rigorous quality control.
  • The number of primary manufacturers capable of producing this API at commercial scale is relatively limited, increasing the strategic importance of existing relationships.
  • Regulatory approvals for API manufacturing sites are critical. Sites must adhere to cGMP standards enforced by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What are the principal sources for conjugated estrogens APIs?

Conjugated estrogens are a mixture of estrogen compounds, primarily derived from natural sources like pregnant mares' urine. The supply chain for these APIs is distinct from synthetic molecules due to its biological origin and complex extraction and purification processes.

• Key API Suppliers and Originators:

  • Wyeth (now part of Pfizer Inc.): Historically, Wyeth was the dominant force in conjugated estrogens with its product Premarin®. Pfizer, through its acquisition of Wyeth, inherited this significant API supply chain. The source of the raw material (urine from pregnant mares) and the subsequent processing are managed internally or through exclusive, long-term contracts.
  • Amneal Pharmaceuticals LLC: As a significant player in generics, Amneal manufactures its own conjugated estrogens API for its generic Premarin® products. This indicates internal API production capabilities or a robust sourcing network.
  • Independent API Manufacturers and Extractors: While proprietary control is high for the branded product, some specialized companies may be involved in the extraction and initial purification of equine estrogens, which are then sold to formulators. These are typically located in regions with large-scale equine breeding operations.
    • Specific Company Identification Challenges: Similar to bazedoxifene acetate, the exact list of independent extractors and intermediate API suppliers is often not publicly disclosed due to commercial sensitivities and the proprietary nature of their processes. Companies specializing in natural product extraction and purification are the most likely participants.

• Supply Chain Dynamics and Challenges:

  • Raw Material Sourcing: The supply of conjugated estrogens is directly tied to the equine industry and the management of pregnant mares. This introduces biological variability and ethical considerations.
  • Manufacturing Process: The process involves collecting urine, extracting and purifying specific estrogen conjugates (e.g., estrone sulfate, estradiol sulfate, equiline sulfate). This is a chemically and biologically complex process requiring specialized facilities.
  • Regulatory Scrutiny: Due to the natural origin and potential for biological contaminants, regulatory oversight from bodies like the FDA is stringent, focusing on purity, potency, and consistency.
  • Market Concentration: The market for conjugated estrogens API is heavily influenced by the historical dominance of the original branded product and the subsequent entry of generic manufacturers.

What are the primary drug product manufacturers utilizing these APIs?

The manufacturers of the final drug products are critical end-users of these APIs, driving demand and influencing the API supplier landscape.

• Bazedoxifene Acetate Drug Product Manufacturers:

  • Pfizer Inc.: Markets Duavee® (bazedoxifene acetate and conjugated estrogens) in the United States and other regions. This is the primary branded product and a significant driver of bazedoxifene acetate demand.
  • Generic Manufacturers: Following patent expiries, numerous generic pharmaceutical companies are likely to develop and market bazedoxifene acetate products. Identification of specific generic drug product manufacturers requires monitoring regulatory approval dockets (e.g., FDA's Abbreviated New Drug Applications - ANDAs). These often include:
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V. (now Viatris)
    • Sun Pharmaceutical Industries Ltd.
    • Amneal Pharmaceuticals LLC

• Conjugated Estrogens Drug Product Manufacturers:

  • Pfizer Inc.: Markets Premarin® (conjugated estrogens) for various indications, including menopausal symptom relief and osteoporosis prevention.
  • Amneal Pharmaceuticals LLC: Manufactures generic versions of conjugated estrogens.
  • Other Generic Companies: A substantial number of generic manufacturers produce conjugated estrogens products, often in various dosage forms (tablets, creams). These are readily available in the market.

What are the geographical concentrations of API manufacturing?

The geographical location of API manufacturing facilities plays a significant role in supply chain costs, regulatory oversight, and geopolitical risk assessment.

• Bazedoxifene Acetate Manufacturing Hubs:

  • India: A leading global hub for API manufacturing due to its cost-effectiveness, skilled workforce, and established regulatory compliance infrastructure. Many CDMOs in India are equipped for complex chemical synthesis.
  • China: Another major global API supplier, particularly for intermediates and less complex molecules. However, Chinese manufacturers are increasingly capable of producing complex APIs like bazedoxifene acetate, especially those with FDA/EMA inspected sites.
  • United States and Europe: While less dominant in terms of sheer volume compared to Asia, some specialized US and European manufacturers maintain API production, often focusing on high-value, complex molecules, or serving as secondary/backup suppliers for Western markets. These facilities typically have very high regulatory standards.

• Conjugated Estrogens API Sourcing and Processing:

  • North America (specifically the US and Canada): Given the reliance on equine sources, processing facilities are often located in regions with significant horse breeding and management operations. Pfizer's historical base in North America for Premarin® production suggests a strong presence here.
  • Europe: Some specialized facilities in European countries with established pharmaceutical industries may also be involved in the extraction and purification of naturally derived compounds.
  • Limited Global Diversification: The specialized nature of obtaining raw materials from equine sources limits the geographical diversification of this particular API supply chain compared to purely synthetic APIs.

What are the key regulatory considerations for these APIs?

Regulatory compliance is paramount for both API manufacturers and drug product formulators. Failure to meet standards can result in significant delays, product recalls, and market access restrictions.

• cGMP Compliance: All API manufacturers must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory agencies like the FDA, EMA, and others. This includes stringent controls over manufacturing processes, quality systems, documentation, and facility maintenance.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. These confidential documents contain detailed information about the API’s manufacturing process, facilities, quality control, and stability. Drug product manufacturers then reference these DMFs in their marketing applications (e.g., NDAs, ANDAs).
• Site Inspections: Regulatory agencies conduct routine inspections of API manufacturing sites to ensure ongoing cGMP compliance. Successful inspection outcomes are critical for maintaining supply to regulated markets.
• Impurity Profiling and Control: For both bazedoxifene acetate and conjugated estrogens, rigorous control and characterization of impurities are essential. This is particularly complex for conjugated estrogens due to their natural origin.
• Stability Studies: Comprehensive stability testing is required to establish appropriate storage conditions and shelf-life for the APIs.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines provide a framework for many of these regulatory requirements, promoting global harmonization.

What are the potential risks in the supply chain?

Understanding potential risks is crucial for supply chain management and business continuity planning.

• Bazedoxifene Acetate Risks:

  • Limited Supplier Pool: A concentrated number of primary manufacturers creates vulnerability to disruptions caused by a single supplier's operational issues (e.g., plant shutdowns, quality failures, regulatory actions).
  • Geopolitical Instability: Reliance on specific geographic regions (e.g., India, China) can expose the supply chain to trade disputes, political unrest, or export restrictions.
  • Intellectual Property (IP) Disputes: For new generic entrants, patent litigation related to the synthesis process or formulation can create supply uncertainties.
  • Raw Material Availability: While bazedoxifene acetate is synthetic, the precursors and key reagents used in its synthesis can be subject to their own supply chain challenges.

• Conjugated Estrogens Risks:

  • Raw Material Dependency: The entire supply chain is dependent on the availability and health of equine populations and the efficiency of urine collection.
  • Biological Variability: Natural products can exhibit inherent variability, requiring robust quality control systems to ensure consistency.
  • Ethical and Public Perception: The sourcing of urine from pregnant mares can attract negative attention and may lead to consumer or regulatory pressure for alternative sourcing.
  • Disease Outbreaks: Epidemics affecting equine populations could severely disrupt raw material supply.
  • Environmental Factors: Changes in land use or agricultural practices in key breeding regions could indirectly impact supply.

Key Takeaways

• Bazedoxifene Acetate Supply: Dominated by specialized API manufacturers, with significant production concentrated in India and China. Pfizer holds a key position as the originator and marketer of the branded product. Generic market entry will expand the number of drug product manufacturers, increasing demand for API from diverse sources.
• Conjugated Estrogens Supply: Characterized by its natural origin, with Pfizer as the historical primary supplier through its Premarin® product. The supply chain is directly linked to equine resources, introducing unique risks and a less diversified geographical manufacturing base compared to synthetic APIs.
• Regulatory Imperative: Strict adherence to cGMP and robust quality systems are non-negotiable for all suppliers. DMFs and successful regulatory inspections are critical gatekeepers for market access.
• Risk Mitigation: Pharmaceutical companies must diversify their API supplier base where feasible, conduct thorough due diligence on manufacturers' regulatory compliance and financial stability, and develop contingency plans to address potential supply chain disruptions, particularly for the more concentrated bazedoxifene acetate market and the biologically dependent conjugated estrogens supply.

Frequently Asked Questions

1. What is the typical lead time for securing a supply of bazedoxifene acetate API from a new manufacturer? Lead times can range from six months to over a year, depending on the manufacturer's current capacity, the complexity of the synthesis, the need for regulatory site audits and DMF filing, and contractual negotiations.

2. Are there any significant differences in the quality or purity of bazedoxifene acetate API supplied by manufacturers in India versus China? Quality and purity are dictated by cGMP compliance and the specific Drug Master File (DMF) submitted to regulatory authorities. While both regions have highly compliant manufacturers, due diligence is required for each supplier to confirm adherence to stringent quality standards.

3. What are the primary challenges in scaling up the production of conjugated estrogens API? The primary challenges include the consistent sourcing of raw material (urine from pregnant mares), managing biological variability, ensuring stringent purification to remove potential contaminants, and maintaining specialized processing facilities that meet regulatory requirements for naturally derived products.

4. Can a drug product manufacturer use an API from a supplier that is not yet FDA-approved but is approved by EMA? No, for the U.S. market, the API must be manufactured at a facility that is acceptable to the FDA, typically meaning it has passed FDA inspections or is referenced in an FDA-accepted DMF. Similarly, for the European market, EMA acceptance is required.

5. What is the outlook for the supply of bazedoxifene acetate as more generic versions enter the market? As more generic versions enter, demand for bazedoxifene acetate API is expected to increase. This may lead to greater competition among API suppliers, potentially driving down prices but also necessitating increased vigilance regarding supplier reliability and quality to ensure adequate supply for multiple generic products.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - Specific URL for DMFs would be ideal if available, otherwise general reference] [2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from [EMA Website - Specific URL for ASMFs would be ideal if available, otherwise general reference] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website - Specific URL for guidelines would be ideal if available, otherwise general reference] [4] Pfizer Inc. (n.d.). Duavee® (bazedoxifene and conjugated estrogens) prescribing information. [Specific product information document] [5] Pfizer Inc. (n.d.). Premarin® (conjugated estrogens) prescribing information. [Specific product information document]